Sinocare(SZ:300298) Xin Lang Cai Jing·2026-01-12 01:32Group 1 - The core viewpoint of the news highlights the trading performance and financing activities of Sanofi Biologicals, indicating a significant increase in stock price and trading volume on January 9, with a net financing purchase of 2.18 million yuan [1] - On January 9, Sanofi Biologicals had a financing balance of 395 million yuan, which accounts for 3.76% of its market capitalization, indicating a high level of financing activity compared to the past year [1] - The company reported a total revenue of 3.453 billion yuan for the first nine months of 2025, reflecting a year-on-year growth of 8.52%, while the net profit attributable to shareholders decreased by 17.36% to 211 million yuan [2] Group 2 - Sanofi Biologicals has cumulatively distributed 1.512 billion yuan in dividends since its A-share listing, with 344 million yuan distributed over the past three years [3] - As of September 30, 2025, the number of shareholders increased by 58.52% to 24,600, while the average circulating shares per person decreased by 37.47% to 18,347 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 3.2967 million shares, while other significant shareholders like Ruiyuan Growth Value Mixed A and Huabao CSI Medical ETF reduced their holdings [3]